Hostname: page-component-745bb68f8f-hvd4g Total loading time: 0 Render date: 2025-01-24T06:38:26.174Z Has data issue: false hasContentIssue false
  • English
  • Français

Progress: Measuring the Benefit

Published online by Cambridge University Press:  02 December 2014

Richard Wennberg  and
Camilla Zimmermann
Richard Wennberg
Affiliation:
Toronto, Ontario
Camilla Zimmermann
Affiliation:
Toronto, Ontario
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the Editor
Information
Canadian Journal of Neurological Sciences , Volume 33 , Issue 2 , May 2006 , pp. 254
Copyright
Copyright © The Canadian Journal of Neurological 2006

References

1. Bussière, M, Wiebe, S. The numbers needed to treat for neurological disorders. Can J Neurol Sci. 2005; 32: 440–9.CrossRefGoogle ScholarPubMed
2. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with a previous stroke or transient ischaemic attack. Lancet. 2001; 358: 1033–41.Google Scholar
3. Wennberg, R, Zimmermann, C. The PROGRESS trial three years later: time for a balanced report of effectiveness. BMJ. 2004; 329: 968–70.Google Scholar
4. Wennberg, R, Zimmermann, C. Perindopril monotherapy and PROGRESS in Europe. BMJ. 2005; 331: 235–6.CrossRefGoogle ScholarPubMed